Analyst Price Target is $49.43
▲ +70.56% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Ventyx Biosciences in the last 3 months. The average price target is $49.43, with a high forecast of $65.00 and a low forecast of $35.00. The average price target represents a 70.56% upside from the last price of $28.98.
Current Consensus is
The current consensus among 7 polled investment analysts is to buy stock in Ventyx Biosciences.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company is developing VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.